Information Provided By:
Fly News Breaks for September 7, 2017
SRPT
Sep 7, 2017 | 05:40 EDT
Credit Suisse analyst Alethia Young raised her price target last night for shares of Sarepta Therapeutics to $81 following yesterday's top line results from the company's Exon 53 study dosed in 25 patients. The analyst now assumes a slightly higher probability of success for ongoing pivotal Essence study. She increased her probability of success to 40% in both exons and keeps an Outperform rating on Sarepta. The shares closed yesterday up $5.65, or 14%, to $46.73.
News For SRPT From the Last 2 Days
There are no results for your query SRPT
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.